Loading clinical trials...
Loading clinical trials...
A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
Conditions
Interventions
secukinumab
Placebo
Locations
105
United States
University Of Alabama
Birmingham, Alabama, United States
Kaiser Permanente Fontana
Fontana, California, United States
University of California LA
Los Angeles, California, United States
Arthritis and Rheum Dise Spec
Aventura, Florida, United States
Integral Rheumatology and Immunology Specialists IRIS
Plantation, Florida, United States
Piedmont Heart Institute
Atlanta, Georgia, United States
Start Date
July 7, 2020
Primary Completion Date
September 13, 2023
Completion Date
September 13, 2023
Last Updated
May 16, 2025
NCT05126277
NCT05538208
NCT07015983
NCT06947460
NCT07107659
NCT07225387
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions